BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
ALBERQUEQUE, NM and SAN DIEGO, CA, Sept. 11, 2017 -- Exagen Diagnostics Inc. (“Exagen”), a commercial stage specialty diagnostic company and exclusive home of AVISE testing, announced today that it has completed two significant capitalization events.
|
|||
The company has entered into a debt financing agreement with an affiliate of Innovatus Capital Partners, LLC (“Innovatus”), to provide Exagen Diagnostics with up to $25 million in term loans. Combined with more than $23 million raised in a Series F equity offering earlier this year, Exagen Diagnostics has raised over $48 million this year to accelerate the commercialization of the company’s proprietary Cell Bound Complement Activation Products (CB-CAPs) technology.
"This funding is a testament to the value we bring to the challenging and costly area of autoimmune disease. Through our unique diagnostic, prognostic and drug monitoring tests we facilitate timely and accurate decision-making so providers can get patients on the road to wellness. This strong capital position will also assists us in maintaining our impressive growth trajectory as we prepare to commercialize our pipeline products and carryout our clinical utility studies“ stated Ron Rocca, Chief Executive Officer of Exagen Diagnostics.
About Exagen Diagnostics
Exagen Diagnostics, Inc. is a College of American Pathologists (CAP) accredited and CLIA certified rheumatology specialty laboratory that focuses on the significant unmet need for accurate and timely diagnosis, prognosis and monitoring of autoimmune connective tissue diseases (CTD). Its groundbreaking solutions address the full continuum of care with tools designed and clinically shown to help physicians deliver accurate, early diagnosis and optimized therapy. For more information, visit www.AviseTest.com
About Innovatus Capital Partners
Innovatus Capital Partners, LLC, is an independent adviser and portfolio management firm with ~$1.7 billion in assets under management. The firm adheres to an investment strategy that identifies distressed, disruptive and growth opportunities in the less obvious market segments across multiple asset categories with a unifying theme of capital preservation, income generation, and upside optionality. Further information can be found at innovatuscp.com.
Exagen, AVISE, and the Exagen and AVISE logos are registered trademarks of Exagen Diagnostics Inc.
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/b12f23f6-e185-4356-b2db-d24493641cc7
Kamal Adawi Exagen Diagnostics, Inc. 760-477-5514 [email protected]
